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To the Editor-in-Chief
Sir,
Rapid diagnosis of medium chain
Acyl Co-A dehydrogenase (MCAD)
deficiency in a newborn by liquid
chromatography/tandem mass spec-
trometry
Medium chain Acyl-CoA dehydro-
genase (MCAD) deficiency is the most
common b-oxidation defect.1,2 Its pre-
sentation varies from acute neonatal
to late-onset and even to adulthood
onset,3,4 and in some cases it is asymp-
tomatic for an entire lifetime.5 The
symptoms are characterised by hypo-
glycaemia, vomiting, seizures, lethargy,
coma, till death. The metabolic disorder
is frequently caused by fasting or viral
febrile illness. Moreover, MCAD defi-
ciency can be responsible for sudden
infant death syndrome (SIDS),6 for per-
manent neurological damage due to
hypoglycaemic encephalopathy,7 and
for Reye-like syndrome.8,9
Molecular analysis of the MCAD
gene in clinically affected patients has
revealed that 80% of patients are
homozygous for a common mutation
985A!G, and 18% are heterozygous
for this mutation.7,10 The delayed, or
not performed, diagnosis of MCAD
deficiency at presentation causes the
deaths of about 20–25% of patients.11,12
Because of its frequency (1:10000–
1:17000 newborns)1,13–15 and high mor-
tality, neonatal screening by electro-
spray ionisation tandem mass
spectrometry (ESI-MS/MS) is highly
recommended.13,16–18 However, in
very rapid and acute neonatal onset,
frequently within 3 days of life,3,19
neonatal screening could be too late
with reference to the worsening of the
gravity of illness. Therefore, clinical
symptoms must lead to laboratory tests
and to diagnosis as soon as possible.
MCAD deficiency diagnosis can be
performed by analysing the acylcarni-
tine profile from a dried blood spot or
plasma spot.24–33 Acylcarnitine analy-
sis was originally performed by high-
performance liquid chromatography
(HPLC), gas chromatography/mass
spectrometry (GC/MS),21 or GC of
organic acids after hydrolysis of carni-
tine esters. These processes are time-
consuming (typical run times are
>30 min) and labour-intensive, thus
limiting high-throughput performance.
We describe here a patient with acute
severe presentation in his third day of
life. In this case a very rapid diagnosis
by LC/MS/MS allowed a complete
recovery before the decompensation
became very important. After dia-
gnosis, LC/MS/MS analyses are also
fundamental for follow-up purpo-
ses during long-term management
therapy.
The patient, a male, was born at term
to non-consanguineous parents from
Tuscany, with a weight of 3360 g. A
brother and a sister are healthy. No
clinical abnormalities were found in
the first day of life. After 48 h of life, he
became hypotonic and hyporeactive.
Abnormal laboratory findings inclu-
ded metabolic aciduria (blood gas
parameters were pH 7.28; pCO2 28.3;
HCO3
 13.1; EB 11.8), high values of
transaminases and lactate, hyperam-
monaemia (291 mM; normal <32 mM),
and hypoglycaemia (10 mg/dL; nor-
mal 70–120 mg/dL). Because of the
presence of these symptoms, a sample
from blood spot paper was immedi-
ately prepared and immediately ana-
lysed by LC/MS/MS. The diagnosis of
MCAD deficiency, due to accumula-
tion of medium chain acylcarnitines
(see later), was made about 1 h after
drawing blood.
Acylcarnitines and labeled stan-
dards of amino acids were purchased
from Cambridge Isotope Laboratories
(Andover, MA, USA); a stock solution
was made in methanol. The standard
concentrations are in the range 500–
2500 mmol/L for amino acids and in the
range 7.6–152 mmol/L for acylcarni-
tines. In order to obtain working solu-
tions, daily dilutions (1:100) were made
using methanol. All chemicals and
solvents were of the highest purity
available from commercial sources,
and were used without any further
purification.
A dried blood spot was punched into
a 1.5-mL tube and 200mL of methanol
containing labeled standards were
added. The sample was shaken on a
vortex system for 20 min, and was then
dried under a nitrogen flow at 508C.
The extracted acylcarnitines and amino
acids were derivatised to butyl esters
using n-butanol plus HCl (3 M) at 658C
for25 min.Afterderivatisation thesam-
ple was dried under a nitrogen flow at
558C and then recovered by 200 mL of
water/acetonitrile (1:1) containing
0.1% formic acid. 40mL of the diluted
sample were injected in flow injection
analysis (FIA) mode for the MS/MS
experiments.
An Applied Biosystems-Sciex
(Toronto, Canada) API 2000 triple-
quadrupole mass spectrometer equip-
ped with a TurboIonSpray source was
employed for this study. The Tur-
boIonSpray source was operated in
positive ion mode with a needle poten-
tial of þ5900 V and with a ‘‘turbo’’ gas
flow of 10 L/min of air heated at 1508C
(nominal heating-gun temperature).
Mass calibration and resolution
adjustments on the resolving quadru-
poles were performed automatically by
using a 104 mol/L solution of PPG
introduced via the built-in infusion
pump. The peak width was set on both
resolving quadrupoles at 0.7 Th (mea-
sured at half height) for all MS and MS/
MS experiments.
Collision-activated dissociation
(CAD) MS/MS was performed in the
LINAC Q2 collision cell, operating
with 10 mTorr pressure of nitrogen as
collision gas. The declustering poten-
tial (DP) and collision energy (CE) were
automatically optimized for acylcarni-
tines and amino acids using the Ana-
lyst 1.1 software. The resulting DP was
þ18 V, and optimal CE was found to be
20 eV (laboratory frame) in the case of
amino acids. A DP ramp (10–55 V) and
a CE ramp (35–50 eV) were needed in
the case of acylcarnitines.
MS and MS/MS spectra were col-
lected in continuous flow mode by
connecting the infusion pump directly
to the TurboIonSpray source. A stan-
dard solution of 10 ng/mL of each
amino acid and acylcarnitine in
water/acetonitrile (1:1) containing
0.1% formic acid was infused at 10 mL/
min. The quantitation experiments
Copyright # 2003 John Wiley & Sons, Ltd.
RCM
Letter to the Editor
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Un
co
rre
cte
d 
Pr
oo
f
were performed using a series 1100
Agilent Technologies (Waldbronn,
Germany) CapPump coupled to an
Agilent Micro ALS autosampler,
both fully controlled by the API 2000
data system. Mobile phase flow rate
was 30 mL/min using water/acetoni-
trile (1:1) containing 0.1% formic acid.
The eluent from the column was
directed to the TurboIonSpray probe.
The acquired data were processed
using the Analyst 1.1 proprietary soft-
ware including the ‘Explore’ option
(for chromatographic and spectral
interpretation) and the ChemoView
software (for quantitative information
generation).
Genomic DNA was extracted from
the patient’s and from his parents’
peripheral blood lymphocytes using
standard methods. The genomic frag-
ments covering all 12 exons and the
exon/intron boundaries of the MCAD-
gene were amplified by a set of primers
located in flanking intronic sequences.
PCR amplification was performed
under the following conditions: initial
denaturation at 948C for 4 min was
followed by 30 cycles with denatura-
tion at 948C for 30 s, annealing tem-
perature of 638C for 30 s, and extension
at 728C for 2 min. All the amplification
reactions were performed in a total
volume of 25 mL containing 2.5 U Poly-
Taq DNA polymerase (Polymed, Sam-
buca-Firenze, Italy), 25 mM of dNTPs,
200 ng forward primer, 200 ng of the
reverse primer and 1XPCR reaction
buffer.
PCR fragments were separated on
a 2% agarose gel containing ethidium
bromide and the bands were visualised
by an UV transilluminator. DNA
products were purified using a
Nucleospin extract kit (Macherey-
Nagel, Du¨ren, Germany), following
the manufacturer’s protocol. The dou-
ble-stranded purified products were
used for direct sequencing with the
same PCR amplification primers. The
sequencing reactions were performed
with Big Dye terminator cycle sequen-
cing ready reaction kit reagents
(Applied Biosystems, Foster City, CA,
USA). The reactions were run on an ABI
PRISM 310 sequencer and were ana-
lysed using Sequencing analysis soft-
ware, version 3.3.
Figure 1 shows a typical MS/MS
profile of a healthy newborn. Figure 2
shows the comparison between a nor-
mal acylcarnitine profile versus one
affected by a MCAD deficiency. The
anomalous ions corresponding to very
high concentrations of hexanoyl car-
nitine (C6), octanoyl carnitine (C8),
decanoyl carnitine and decenoyl carni-
tine (C10:1) are clearly observed at m/z
316, 344, 372 and 370, respectively, only
in the MCADD-affected profile. The
amino acid profile was normal. After
diagnosis the patient was supplied
intravenously with glucose and with
insulin as emergency therapy. These
administrations gave high cellular
energy availability, halting lipolithic
pathway activation. In addition, a sup-
plementation f l-carnitine was needed
to remove accumulation of toxic inter-
mediates. Figure 3 shows the MCAD
deficiency acylcarnitine profile during
emergency therapy (8, 18, and 48 h
post-diagnosis). The use of an LC/
MS/MS system during the first 48 h
post-diagnosis permitted the evalua-
tion of the removal of the toxic acylcar-
nitines (Table 1). After the first 48 h, a
Figure 1. ESI-Q1MS/MS profiles of acylcarnitines and amino acids of a healthy newborn.
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Figure 2Q1. Normal acylcarnitine profile compared with one from a patient with MCAD deficiency.
Figure 3Q1. Acylcarnitine profile of a patient with MCAD deficiency during emergency therapy.
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new management regime was started,
consisting of an administration of a
milk specific for b-oxidation defects,
containing no fats but only carbohy-
drates and proteins, and in addition an
aliquot of human milk containing fats,
that provided 15–16% of the total daily
intake of kilocalories. Figure 4 shows
the acylcarnitine MS/MS profiles dur-
ing the 48 h after the start of this
management regime. The values of
the increase in medium chain acylcar-
nitines allowed the evaluation that, in
this patient, the MCAD residue activity
was probably very low. Therefore, the
management regime was corrected
with respect to the human milk admin-
istration, changing to 8% the contribu-
tion of fats to the total daily intake of
kilocalories.
Figure 5 shows the MCADD-affected
acylcarnitine profile following the defi-
nitive long-term management regime,
in comparison with a normal profile.
Molecular analysis indicated that
the patient was homozygous for the
known K329E mutation. This mutation
is due to the transition 985A!G,
which maps on exon 11 of the MCAD
gene. His parents were heterozygous
for this mutation. The K329E amino
acid change is the most common
mutation in the Caucasoid group of
humans. Some authors have estimated
its frequency to be about 90% of all
MCAD mutations.22,23
In conclusion, the newborn screen-
ing method is characterised by a simple
sample preparation and the instrumen-
tal analysis time is less than 3.3 min. In
this case we performed the diagnosis
about 1 h after receiving the blood spot
paper, allowing the start of an emer-
gency therapy immediately. The lim-
itation of Italian newborn screening is
that the drawing blood procedure must
be performed after 48 h post-birth,
which does not allow diagnosis of
some acute neonatal onset pathologies.
In these cases the driving force is clini-
cal symptoms which indicate a poten-
tial metabolic disease. After this
manifestation of clinical symptoms a
fundamental role is played by an LC/
Table 1. Decrease in levels of medium chain acylcarnitines during emergency
therapy
C6 C8 C10 C10:1
Diagnosis 3.35 26.7 3.03 0.897
8 hours PD 2.6 19 1.79 0.65
18 hours PD 1.43 3.28 0.269 0.225
48 hours PD 0.457 1.22 0.104 0.12
Normal values* 0.06–0.24 0.02–0.23 0.03–0.2 0.05–0.24
C6, Hexanoyl carnitine; C8, octanoyl carnitine; C10, decanoyl carnitine; C10:1, decenoyl
carnitine; PD, post-diagnosis.
* 5th–95th percentile.
Figure 4Q1. Restoration of medium chain acylcarnitines during the 48 h after the start of the management regime.
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MS/MS system that permits a very fast
identification of defects in comparison
with other analytical techniques.
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